Astellas' fezolinetant fails in Asia trial after earlier successes

15 March 2022

Just last week, Astellas Pharma (TYO: 4503) announced positive top-line results from the Phase III SKYLIGHT 4 trial investigating fezolinetant in moderate to severe vasomotor symptoms associated with menopause (VMS).

Those results are supporting regulatory filing submissions in western markets and would have prompted expectations of similar results in the similar Phase III MOONLIGHT 1 trial study in Asia.

Instead, the Japanese drugmaker has now announced that its investigational oral, non-hormonal compound did not meet the pre-defined endpoints for efficacy in MOONLIGHT 1. This was based on the 12-week data analysis in 302 participants testing fezolinetant 30 mg once daily in women in China, Korea and Taiwan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK